The interleukin-6 pathway and atherosclerosis
Authors:
- S Matthijs BoekholdtSBS Matthijs Boekholdt
- Erik Sg StroesESErik Sg Stroes
- 1 March 2012
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 379 (9822) , 1176-1178
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) TrialCardiovascular Drugs and Therapy, 2011
- Atherosclerosis: current pathogenesis and therapeutic optionsNature Medicine, 2011
- Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndromeAmerican Heart Journal, 2011
- Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)American Heart Journal, 2011
- Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant dataBMJ, 2011
- Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart DiseaseJAMA, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Genetically Elevated C-Reactive Protein and Ischemic Vascular DiseaseNew England Journal of Medicine, 2008
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Interindividual and Intraindividual Variability in Plasma Fibrinogen, TPA Antigen, PAI Activity, and CRP in Healthy, Young Volunteers and Patients With Angina PectorisArteriosclerosis, Thrombosis, and Vascular Biology, 1996